Concepedia

Munjal Patel

MP

10

Publications

626

Citations

10

H-Index

2006

Active since

Affiliations

Merck & Co., Inc., Rahway, NJ, USA (United States)(Current)

Munjal Patel is an author at Merck & Co., Inc., Rahway, NJ, USA (United States) specializing in medicine, hiv, and aids pathogenesis.

ORCID

Top concepts

Publications per year

2006–2024

10

Publications

10

A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study)

Ivan Titov, Richard G. Wunderink, Antoine Roquilly et al. · Clinical Infectious Diseases · 2020 · 213 citations · Full text

Effective expansion of alloantigen-specific Foxp3 <sup>+</sup> CD25 <sup>+</sup> CD4 <sup>+</sup> regulatory T cells by dendritic cells during the mixed leukocyte reaction

Sayuri Yamazaki, Munjal Patel, A. M. Harper et al. · Proceedings of the National Academy of Sciences · 2006 · 183 citations · Full text

Recombinant ADAMTS13 in Congenital Thrombotic Thrombocytopenic Purpura

Marie Scully, Ana G. Antun, Spero R. Cataland et al. · New England Journal of Medicine · 2024 · 69 citations

Safety and pharmacokinetics of islatravir subdermal implant for HIV-1 pre-exposure prophylaxis: a randomized, placebo-controlled phase 1 trial

Randolph P. Matthews, Munjal Patel, Stephanie E. Barrett et al. · Nature Medicine · 2021 · 65 citations

, , +8

Population pharmacokinetic/pharmacodynamic assessment of imipenem/cilastatin/relebactam in patients with hospital‐acquired/ventilator‐associated bacterial pneumonia

Munjal Patel, Francesco Bellanti, Naveen M. Daryani et al. · Clinical and Translational Science · 2021 · 30 citations · Full text

Rows per page

1–5 of 10